Well I'm thinking this news should give it the boost for 10-20% gain. Hopefully for us it does.
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances - Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved
- On Track to Regain Compliance with All Nasdaq Listing Requirements
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.